Abstract
Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
CNS & Neurological Disorders - Drug Targets
Title:The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Volume: 12 Issue: 2
Author(s): Domenico De Berardis, Stefano Marini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Monica Mazza, Alessandro Valchera, Michele Fornaro, Marilde Cavuto, Venkataramanujam Srinivasan, Gianna Sepede, Giovanni Martinotti and Massimo Di Giannantonio
Affiliation:
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
Abstract: Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Export Options
About this article
Cite this article as:
Berardis Domenico De, Marini Stefano, Iasevoli Felice, Tomasetti Carmine, Bartolomeis Andrea de, Mazza Monica, Valchera Alessandro, Fornaro Michele, Cavuto Marilde, Srinivasan Venkataramanujam, Sepede Gianna, Martinotti Giovanni and Giannantonio Massimo Di, The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/1871527311312020012
DOI https://dx.doi.org/10.2174/1871527311312020012 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG
Current Alzheimer Research Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer’s Disease and Other Inflammation-related Pathologies
Current Alzheimer Research Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis
Current Neuropharmacology Extracellular Superoxide Dismutase (EC-SOD) Quenches Free Radicals and Attenuates Age-Related Cognitive Decline: Opportunities for Novel Drug Development in Aging
Current Alzheimer Research Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets